Pfizer, Repligen unite to develop spinal muscular atrophy drugs

Pfizer and Repligen will develop the latter's spinal muscular atrophy program including experimental SMA drug RG3039 as part of a licensing deal. RG3039, which was licensed from patient advocacy group Families of SMA, holds orphan-drug status in the U.S. and Europe as well as fast-track designation in the U.S. Repligen will receive $5 million upfront and as much as $65 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC